Indivior Advances Treatment for Opioid Use Disorder
Indivior PLC, known for its commitment to combating opioid addiction, announced an exciting development regarding SUBLOCADE® (buprenorphine extended-release). This monthly injectable formulation, designed to treat moderate to severe opioid use disorder (OUD), has recently been granted Priority Review status by the U.S. Food and Drug Administration (FDA). This recognition signals a potential advancement in treatment options for individuals grappling with OUD.
Priority Review Designation
The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for the submission of February 7, 2025. This shorter review timeline reflects the urgency and importance of the proposed changes, which aim to broaden the label for SUBLOCADE to include alternative injection sites. These sites now encompass the thigh, buttock, and back of the arm, which will improve accessibility for patients during both induction and maintenance phases of treatment.
A Response to Patient Needs
The updates proposed through the Prior Approval Supplement (PAS) are designed to meet significant patient and healthcare provider needs. By incorporating alternative injection sites and implementing a rapid induction protocol, SUBLOCADE could greatly improve the treatment experience for many. This protocol will allow patients to receive treatment after just one hour of observation, dramatically reducing the previous seven-day requirement associated with first doses of oral buprenorphine.
Expanding Treatment Access
Indivior’s innovation in treatment strategy is pivotal, especially for those with long-standing history of opioid use, including fentanyl dependency. The ability to utilize multiple injection sites, along with expedited treatment initiation, is set to enhance overall patient experience and access to vital care.
Understanding SUBLOCADE
As a critical component of Indivior's therapeutic lineup, SUBLOCADE functions as a long-acting injectable buprenorphine treatment. This involves patients initially stabilizing on a buprenorphine-containing product followed by adjustments over a minimum of seven days. The incorporation of instant induction protocols suggests a significant shift in how OUD can be managed effectively.
Continuing Commitment to Safety
While expanding the application of SUBLOCADE, Indivior remains staunchly committed to patient safety. The company emphasizes that treatment should be part of a holistic plan inclusive of counseling and support, which are crucial in addressing the complexities of addiction and recovery.
Warning about the risks associated with intravenous administration of SUBLOCADE remains clear. Administering the medication in this manner could lead to serious harm or death, underlining the necessity of rigorous adherence to prescribed protocols and guidelines.
About Indivior and Its Vision
Indivior is dedicated to reshaping the landscape of substance use disorder treatment. Their vision is to ensure that all patients worldwide can access evidence-based therapies for chronic conditions and associated disorders. Over 1,000 employees are devoted to this mission, delivering innovative treatments across more than 30 countries, supporting countless individuals on their path to recovery and health.
Frequently Asked Questions
What is SUBLOCADE?
SUBLOCADE is an extended-release injectable medication used for treating moderate to severe opioid use disorder.
What updates are being proposed for SUBLOCADE?
The proposed updates include the addition of alternative injection sites and a rapid induction protocol enabling quicker treatment initiation.
What does Priority Review mean?
Priority Review indicates that the FDA aims to take action on the application within six months, significantly faster than the standard review timeframe.
Why is safety emphasized in the use of SUBLOCADE?
Due to the serious risks associated with intravenous administration, patient safety measures and education are paramount when using SUBLOCADE.
How does Indivior support its patients?
Indivior emphasizes a comprehensive treatment strategy, including counseling and ongoing support, to enhance recovery from opioid use disorder.
